Research progress and optimization strategies for early screening of type 1 diabetes

Qi-Jun SONG, Yan SUN

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1310-1316.

PDF(766 KB)
HTML
PDF(766 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1310-1316. DOI: 10.7499/j.issn.1008-8830.2505123
SERIES REVIEW—DIAGNOSIS AND TREATMENT OF GROWTH DISORDERS

Research progress and optimization strategies for early screening of type 1 diabetes

Author information +
History +

Abstract

The prevalence of type 1 diabetes (T1DM) is increasing annually, and its complications seriously impair the quality of life of affected children. Early screening for T1DM helps reduce the occurrence of diabetic ketoacidosis, protect β-cell function, and delay disease onset in high-risk populations. This article summarizes current domestic and international screening technologies for T1DM. Screening methods remain centered on detection of diabetes-related antibodies and glycometabolic markers, while factors related to disease pathogenesis hold promise as sensitive screening markers. Expanding T1DM screening in China is expected to improve early diagnosis and treatment.

Key words

Type 1 diabetes / Early screening / Disease mechanism / Diabetes-related antibody

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Qi-Jun SONG , Yan SUN. Research progress and optimization strategies for early screening of type 1 diabetes[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(11): 1310-1316 https://doi.org/10.7499/j.issn.1008-8830.2505123

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
[1]
中华医学会糖尿病学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会内分泌学分会, 等. 中国1型糖尿病诊治指南（2021版）[J]. 中华糖尿病杂志, 2022, 14(11): 1143-1250. DOI: 10.3760/cma.j.cn115791-20220916-00474 .
Cited in this article [2]
[2]
Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study[J]. Lancet Diabetes Endocrinol, 2022, 10(10): 741-760. DOI: 10.1016/S2213-8587(22)00218-2 .
https://www.ncbi.nlm.nih.gov/pubmed/36113507
Cited in this article [1]
[3]
Gomez P, Sanchez J. Type 1 diabetes screening and diagnosis[J]. Endocrinol Metab Clin North Am, 2024, 53(1): 17-26. DOI: 10.1016/j.ecl.2023.09.008 .
https://www.ncbi.nlm.nih.gov/pubmed/38272595
Cited in this article [1]
[4]
Moore DJ, Leibel NI, Polonsky W, et al. Recommendations for screening and monitoring the stages of type 1 diabetes in the immune therapy era[J]. Int J Gen Med, 2024, 17: 3003-3014. PMCID: PMC11247126. DOI: 10.2147/IJGM.S438009 .
https://www.ncbi.nlm.nih.gov/pubmed/39011423
Cited in this article [3]
[5]
Haller MJ, Bell KJ, Besser REJ, et al. ISPAD clinical practice consensus guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes[J]. Horm Res Paediatr, 2024, 97(6): 529-545. PMCID: PMC11854978. DOI: 10.1159/000543035 .
https://www.ncbi.nlm.nih.gov/pubmed/39662065
Cited in this article [8]
[6]
Liu C, Yuan YC, Guo MN, et al. Incidence of type 1 diabetes may be underestimated in the Chinese population: evidence from 21.7 million people between 2007 and 2017[J]. Diabetes Care, 2021, 44(11): 2503-2509. PMCID: PMC8546282. DOI: 10.2337/dc21-0342 .
https://www.ncbi.nlm.nih.gov/pubmed/34413068
Cited in this article [1]
[7]
Food and Drug Administration. FDA approves first drug that can delay onset of type 1 diabetes[EB/OL]. (2023-01-01)[2025-04-23].
https://www.fda.gov/media/164864/download
Cited in this article [1]
[8]
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes[J]. N Engl J Med, 2019, 381(7): 603-613. PMCID: PMC6776880. DOI: 10.1056/NEJMoa1902226 .
https://www.ncbi.nlm.nih.gov/pubmed/31180194
Cited in this article [1]
[9]
Tatovic D, Narendran P, Dayan CM. A perspective on treating type 1 diabetes mellitus before insulin is needed[J]. Nat Rev Endocrinol, 2023, 19(6): 361-370. DOI: 10.1038/s41574-023-00816-5 .
https://www.ncbi.nlm.nih.gov/pubmed/36914759
Cited in this article [1]
[10]
Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: a status report and perspective[J]. Diabetes, 2022, 71(4): 610-623. PMCID: PMC9114719. DOI: 10.2337/dbi20-0054 .
https://www.ncbi.nlm.nih.gov/pubmed/35316839
Cited in this article [1]
[11]
孙肖霄, 黄干, 谢志国, 等. 1型糖尿病遗传学研究进展[J]. 中华医学杂志, 2020, 100(10): 793-796. DOI: 10.3760/cma.j.cn112137-20190621-01394 .
Cited in this article [5]
[12]
Herold KC, Delong T, Perdigoto AL, et al. The immunology of type 1 diabetes[J]. Nat Rev Immunol, 2024, 24(6): 435-451. PMCID: PMC7616056. DOI: 10.1038/s41577-023-00985-4 .
https://www.ncbi.nlm.nih.gov/pubmed/38308004
Cited in this article [7]
[13]
Du M, Li S, Jiang J, et al. Advances in the pathogenesis and treatment strategies for type 1 diabetes mellitus[J]. Int Immunopharmacol, 2025, 148: 114185. DOI: 10.1016/j.intimp.2025.114185 .
https://www.ncbi.nlm.nih.gov/pubmed/39893858
Cited in this article [1]
[14]
Buschard K. The etiology and pathogenesis of type 1 diabetes: a personal, non-systematic review of possible causes, and interventions[J]. Front Endocrinol (Lausanne), 2022, 13: 876470. PMCID: PMC9452747. DOI: 10.3389/fendo.2022.876470 .
https://www.ncbi.nlm.nih.gov/pubmed/36093076
Cited in this article [5]
[15]
Carré A, Vecchio F, Flodström-Tullberg M, et al. Coxsackievirus and type 1 diabetes: diabetogenic mechanisms and implications for prevention[J]. Endocr Rev, 2023, 44(4): 737-751. DOI: 10.1210/endrev/bnad007 .
https://www.ncbi.nlm.nih.gov/pubmed/36884282
Cited in this article [1]
[16]
Quattrin T, Haller MJ, Steck AK, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes[J]. N Engl J Med, 2020, 383(21): 2007-2017. DOI: 10.1056/NEJMoa2006136 .
https://www.ncbi.nlm.nih.gov/pubmed/33207093
Cited in this article [1]
[17]
Lledó-Delgado A, Preston-Hurlburt P, Currie S, et al. Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes[J]. J Clin Invest, 2024, 134(18): e177492. PMCID: PMC11405034. DOI: 10.1172/JCI177492 .
https://www.ncbi.nlm.nih.gov/pubmed/39137044
Cited in this article [1]
[18]
Atkinson MA, Mirmira RG. The pathogenic "symphony" in type 1 diabetes: a disorder of the immune system, β cells, and exocrine pancreas[J]. Cell Metab, 2023, 35(9): 1500-1518. PMCID: PMC10529265. DOI: 10.1016/j.cmet.2023.06.018 .
https://www.ncbi.nlm.nih.gov/pubmed/37478842
Cited in this article [2]
[19]
Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes[J]. Diabetes Care, 2024, 47(8): 1276-1298. PMCID: PMC11381572. DOI: 10.2337/dci24-0042 .
https://www.ncbi.nlm.nih.gov/pubmed/38912694
Cited in this article [3]
[20]
中华医学会糖尿病学分会, 中华医学会儿科学分会, 中华医学会内分泌学分会, 等. 中国1型糖尿病高危人群筛查、监测与管理专家共识（2024版）[J]. 中华糖尿病杂志, 2024, 16(11): 1183-1199. DOI: 10.3760/cma.j.cn115791-20241001-00592 .
Cited in this article [6]
[21]
March CA, Becker DJ, Libman IM. Nutrition and obesity in the pathogenesis of youth-onset type 1 diabetes and its complications[J]. Front Endocrinol (Lausanne), 2021, 12: 622901. PMCID: PMC8021094. DOI: 10.3389/fendo.2021.622901 .
https://www.ncbi.nlm.nih.gov/pubmed/33828529
Cited in this article [2]
[22]
Fu Y, Zhang C, Gu Y, et al. Establishing reference intervals for islet autoantibodies in Han Chinese type 1 diabetes[J]. Scand J Clin Lab Invest, 2021, 81(8): 641-648. DOI: 10.1080/00365513.2021.2001564 .
https://www.ncbi.nlm.nih.gov/pubmed/34779329
Cited in this article [1]
[23]
Vehik K, Bonifacio E, Lernmark Å, et al. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study[J]. Diabetes Care, 2020, 43(9): 2066-2073. PMCID: PMC7440899. DOI: 10.2337/dc19-2547 .
https://www.ncbi.nlm.nih.gov/pubmed/32641373
Cited in this article [1]
[24]
Brenu EW, Harris M, Hamilton-Williams EE. Circulating biomarkers during progression to type 1 diabetes: a systematic review[J]. Front Endocrinol (Lausanne), 2023, 14: 1117076. PMCID: PMC9935596. DOI: 10.3389/fendo.2023.1117076 .
https://www.ncbi.nlm.nih.gov/pubmed/36817583
Cited in this article [1]
[25]
Zhong T, Li X, Lei K, et al. CXCL12-CXCR4 mediates CD57+ CD8+ T cell responses in the progression of type 1 diabetes[J]. J Autoimmun, 2024, 143: 103171. DOI: 10.1016/j.jaut.2024.103171 .
https://www.ncbi.nlm.nih.gov/pubmed/38306953
Cited in this article [1]
[26]
Schroderus AM, Pitkänen V, Ekman I, et al. Temporal alterations in CD8+ T cells during the progression from stage 1 to stage 3 type 1 diabetes[J]. Diabetes, 2024, 73(10): 1705-1715. DOI: 10.2337/db24-0159 .
https://www.ncbi.nlm.nih.gov/pubmed/38967999
Cited in this article [1]
[27]
Barcenilla H, Åkerman L, Pihl M, et al. Mass cytometry identifies distinct subsets of regulatory T cells and natural killer cells associated with high risk for type 1 diabetes[J]. Front Immunol, 2019, 10: 982. PMCID: PMC6509181. DOI: 10.3389/fimmu.2019.00982 .
https://www.ncbi.nlm.nih.gov/pubmed/31130961
Cited in this article [1]
[28]
Harms RZ, Lorenzo-Arteaga KM, Ostlund KR, et al. Abnormal T cell frequencies, including cytomegalovirus-associated expansions, distinguish seroconverted subjects at risk for type 1 diabetes[J]. Front Immunol, 2018, 9: 2332. PMCID: PMC6204396. DOI: 10.3389/fimmu.2018.02332 .
https://www.ncbi.nlm.nih.gov/pubmed/30405601
Cited in this article [1]
[29]
Ferreira-Hermosillo A, Santana-Sánchez P, Vaquero-García R, et al. Circulating T cell subsets in type 1 diabetes[J]. Cells, 2025, 14(1): 48. PMCID: PMC11719944. DOI: 10.3390/cells14010048 .
https://www.ncbi.nlm.nih.gov/pubmed/39791749
Cited in this article [1]
[30]
Fazeli P, Talepoor AG, Faghih Z, et al. The frequency of CD4+ and CD8+ circulating T stem cell memory in type 1 diabetes[J]. Immun Inflamm Dis, 2022, 10(10): e715. PMCID: PMC9500591. DOI: 10.1002/iid3.715 .
https://www.ncbi.nlm.nih.gov/pubmed/36169248
Cited in this article [1]
[31]
Jiang Z, Ren W, Liang H, et al. HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetes[J]. Diabetologia, 2021, 64(9): 2026-2036. PMCID: PMC8382651. DOI: 10.1007/s00125-021-05476-6 .
https://www.ncbi.nlm.nih.gov/pubmed/34023962
Cited in this article [2]
[32]
Zhu M, Xu K, Chen Y, et al. Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study[J]. Diabetes Care, 2019, 42(8): 1414-1421. DOI: 10.2337/dc18-2023 .
https://www.ncbi.nlm.nih.gov/pubmed/31152121
Cited in this article [2]
[33]
Schirru E, Rossino R, Diana D, et al. HLA genotyping in children with celiac disease allows to establish the risk of developing type 1 diabetes[J]. Clin Transl Gastroenterol, 2024, 15(7): e00710. PMCID: PMC11272246. DOI: 10.14309/ctg.0000000000000710 .
https://www.ncbi.nlm.nih.gov/pubmed/38713138
Cited in this article [1]
[34]
Li J, Zhang M, Zhang S, et al. CTSG polymorphisms in Chinese children with type 1 diabetes mellitus[J]. J Trop Pediatr, 2024, 70(4): fmae017. DOI: 10.1093/tropej/fmae017 .
https://www.ncbi.nlm.nih.gov/pubmed/39122654
Cited in this article [1]
[35]
Zhan S, Xu D, Ling C, et al. Screening of key pathogenic genes of type 1 diabetes in children[J]. Transl Pediatr, 2023, 12(4): 709-718. PMCID: PMC10167398. DOI: 10.21037/tp-23-201 .
https://www.ncbi.nlm.nih.gov/pubmed/37181023
Cited in this article [1]
[36]
Galderisi A, Carr ALJ, Martino M, et al. Quantifying beta cell function in the preclinical stages of type 1 diabetes[J]. Diabetologia, 2023, 66(12): 2189-2199. PMCID: PMC10627950. DOI: 10.1007/s00125-023-06011-5 .
https://www.ncbi.nlm.nih.gov/pubmed/37712956
Cited in this article [2]
[37]
Baidal DA, Warnock M, Xu P, et al. Oral glucose tolerance test measures of first-phase insulin response and their predictive ability for type 1 diabetes[J]. J Clin Endocrinol Metab, 2022, 107(8): e3273-e3280. PMCID: PMC9282258. DOI: 10.1210/clinem/dgac285 .
https://www.ncbi.nlm.nih.gov/pubmed/35524749
Cited in this article [1]
[38]
Jacobsen LM, Bundy BN, Ismail HM, et al. Index60 is superior to HbA1c for identifying individuals at high risk for type 1 diabetes[J]. J Clin Endocrinol Metab, 2022, 107(10): 2784-2792. PMCID: PMC9516117. DOI: 10.1210/clinem/dgac440 .
https://www.ncbi.nlm.nih.gov/pubmed/35880956
Cited in this article [1]
[39]
Nathan BM, Redondo MJ, Ismail H, et al. Index60 identifies individuals at appreciable risk for stage 3 among an autoantibody-positive population with normal 2-hour glucose levels: implications for current staging criteria of type 1 diabetes[J]. Diabetes Care, 2022, 45(2): 311-318. PMCID: PMC8914436. DOI: 10.2337/dc21-0944 .
https://www.ncbi.nlm.nih.gov/pubmed/34853027
Cited in this article [1]

Footnotes

所有作者声明无利益冲突。

PDF(766 KB)
HTML

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉